Paper39337463
Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer.
Maimaitijiang A and 6 others. Int J Mol Sci, 2024. Cited by 20 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer. Papers, record 39337463. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39337463
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Resistance, Neoplasm | Major topic |
| Neoplasms | Major topic |
| Drug Resistance, Multiple | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Nanoparticles | |
| Drug Delivery Systems | |
| Animals | |
| Nanomedicine |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| (2023D01C202) | the Natural Science Foundation of Xinjiang Uygur Autonomous Region | PubMed | ||
| (2023B02030-1, 2023B02030-2, and 2023B02030-3) | the Key Research and Development Program in the Xinjiang Uygur Autonomous Region | PubMed | ||
| (2023TSYCLJ0043) | Tianshan Talent Training Program | PubMed | ||
| (XJEDU2023P017) | and the Autonomous Region Universities Basic Research Funds Research Projects-Cultivation Projects | PubMed |
Source PubMed
References145
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9822694 | Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9822694 | PubMed |
| 2 | 31178121 | A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. | Cell | 2019 | https://conductscience.org/library/papers/31178121 | PubMed |
| 3 | 30194528 | Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades. | Drug Deliv Transl Res | 2019 | https://conductscience.org/library/papers/30194528 | PubMed |
| 4 | 10815920 | Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. | Clin Cancer Res | 2000 | https://conductscience.org/library/papers/10815920 | PubMed |
| 5 | 27943612 | One-Step Microfluidic Synthesis of Nanocomplex with Tunable Rigidity and Acid-Switchable Surface Charge for Overcoming Drug Resistance. | Small | 2017 | https://conductscience.org/library/papers/27943612 | PubMed |
| 6 | 37855250 | Multimodal Nanoplatform with ROS Amplification to Overcome Multidrug Resistance in Prostate Cancer via Targeting P-Glycoprotein and Ferroptosis. | Adv Healthc Mater | 2024 | https://conductscience.org/library/papers/37855250 | PubMed |
| 7 | 36635755 | Overcoming multidrug-resistant lung cancer by mitochondrial-associated ATP inhibition using nanodrugs. | J Nanobiotechnology | 2023 | https://conductscience.org/library/papers/36635755 | PubMed |
| 8 | 11747344 | Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. | Br J Cancer | 2001 | https://conductscience.org/library/papers/11747344 | PubMed |
| 9 | 30765258 | Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30765258 | PubMed |
| 10 | 27292613 | Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. | Acta Pharmacol Sin | 2016 | https://conductscience.org/library/papers/27292613 | PubMed |
| 11 | 28123572 | Solid lipid nanoparticles with TPGS and Brij 78: A co-delivery vehicle of curcumin and piperine for reversing P-glycoprotein-mediated multidrug resistance in vitro. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28123572 | PubMed |
| 12 | 31561494 | New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31561494 | PubMed |
| 13 | 32795847 | ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cells. | J Photochem Photobiol B | 2020 | https://conductscience.org/library/papers/32795847 | PubMed |
| 14 | 22761337 | HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. | Cancer Res | 2012 | https://conductscience.org/library/papers/22761337 | PubMed |
| 15 | 27405391 | Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene-dependent multidrug resistance. | J Biomed Mater Res B Appl Biomater | 2017 | https://conductscience.org/library/papers/27405391 | PubMed |
| 16 | 31245292 | Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids. | Front Oncol | 2019 | https://conductscience.org/library/papers/31245292 | PubMed |
| 17 | 22275822 | Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. | Int J Nanomedicine | 2012 | https://conductscience.org/library/papers/22275822 | PubMed |
| 18 | 33316872 | Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/33316872 | PubMed |
| 19 | 31858458 | Folate-Gold-Bilirubin Nanoconjugate Induces Apoptotic Death in Multidrug-Resistant Oral Carcinoma Cells. | Eur J Drug Metab Pharmacokinet | 2020 | https://conductscience.org/library/papers/31858458 | PubMed |
| 20 | 22448244 | Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. | PLoS One | 2012 | https://conductscience.org/library/papers/22448244 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42589703 | Pro-Apoptotic Organometallic Sn(IV) Bis-Organosilane Benzoate Complexes with Sustained Reduction in Cell Viability Under Resistance-like Conditions in Colorectal Cancer Cells. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589703 | PubMed |
| 42488707 | Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42488707 | PubMed |
| 42388631 | Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance. | Front Oncol | 2026 | https://conductscience.org/library/papers/42388631 | PubMed |
| 41278192 | Plant-derived extracellular vesicles: an alternative and complementary therapeutic approach for genitourinary tumors. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/41278192 | PubMed |
| 41255464 | Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41255464 | PubMed |
| 41182526 | Re-sensitization of cancer multidrug resistance through P-gp, MRP1 and BCRP modulation: advances in terpenoids based cancer therapy. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41182526 | PubMed |
| 40867257 | Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40867257 | PubMed |
| 40574091 | Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40574091 | PubMed |
| 40573290 | Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40573290 | PubMed |
| 40482009 | Unraveling novel mechanisms of ATP-Binding cassette (ABC) transporter in insulin Resistance-induced amyloidogenesis. | Metab Brain Dis | 2025 | https://conductscience.org/library/papers/40482009 | PubMed |
| 39978779 | Plant-derived extracellular vesicles as nanocarriers for combination therapy enhancing paclitaxel-based regimens in breast cancer. | BMB Rep | 2025 | https://conductscience.org/library/papers/39978779 | PubMed |
| 39886464 | Application of nanomaterials in precision treatment of lung cancer. | iScience | 2025 | https://conductscience.org/library/papers/39886464 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39337463
GET https://conductscience.org/api/papers/v1/39337463/references?page=2